Background/Aims: Hemobilia is a rare cause of upper gastrointestinal bleeding. Endoscopic retrograde cholangiopancreaticography (ERCP) is considered to be an excellent diagnostic and treatment modality. Thirty-seven cases of hemobilia with different underlying pathologies were analyzed to illustrate clinical features and to evaluate the role of endoscopic management. Methods: A total of 37 patients (26 men and 11 women; mean age, 66.2±15.3 years) who were confirmed to have hemobilia by ERCP in a single center from 2000 to 2010 were reviewed retrospectively. Patients with iatrogenic causes of hemobilia were excluded in this study. Results: The causes of hemobilia were hepatocellular carcinoma in 14, bile duct and gallbladder malignancies in 12, common bile duct stones with cholangitis in 4, acute cholecystitis in 4, and pancreatic cancer in 2 patients. The clinical features of hemobilia were jaundice (89.2%), abdominal pain (78.4%), and melena (13.5%). The cholangiographic findings of hemobilia were amorphous filling defects in 15, tubular filling defects in 6, and cast-like filling defects in 6 patients. Endoscopic management included endoscopic nasobiliary drainage in 26 patients and endoscopic retrograde biliary drainage in 7 patients. Biliary obstruction caused by hemobilia was successfully treated with endoscopic biliary drainages in most cases. Conclusions: The most common non-iatrogenic causes of hemobilia were hepatobiliary malignancies, and the majority of patients presented with jaundice and abdominal pain. Endoscopic biliary drainage is recommended as the initial management to control biliary obstruction. (Korean J Gastroenterol 2012;59:296-302) 
INTRODUCTION
Since the term 'hemobilia' was first used by Values are presented as the mean±SD, n (%), or the mean (range). M, male; F, female; WBC, white blood cells; Hb, hemoglobin; T-bil, total bilirubin.
triad' of hemobilia. 2 Moreover, hemobilia is frequently associated with biliary obstruction and subsequent acute cholangitis.
In the past, the most common cause of hemobila was accidental trauma, followed by iatrogenic injury, such as liver biopsy or percutaneous transhepatic cholangiography (PTC).
Various conditions associated with hemobilia, such as cholecystitis, cholangitis, coagulopathies, vascular malformations, and hepatobiliary tumors, have been increasingly reported. A high index of suspicion is needed for the diagnosis of hemobilia. Unless there is a history of trauma or injury, hemobilia is not easy to recognize in the early stage. [3] [4] [5] Of the available modalities, ERCP has played a significant role in the diagnosis and treatment of hemobilia. The purpose of this study was to analyze 37 cases of non-iatrogenic hemobilia, which were all confirmed by ERCP in our hospital, to identify the etiology and clinical manifestations of hemobilia, and to present the role for endoscopic management of hemobilia. 
SUBJECTS AND METHODS

RESULTS
Clinical features
The mean age was 66.2±15.3 years (range, 26-89 years).
The male-to-female ratio was 2. 
Etiology of hemobilia
Of the 37 cases, there were 28 cases of malignancy and 8 cases of inflammation. Among the hemobilia associated with malignancy, 14 cases were due to hepatocellular carcinoma, 10 cases due to cholangiocarcinoma, 2 cases due to The cause of the remaining 1 case was unknown (Table 2 ).
Cholangiographic findings
Endoscopic retrograde cholangiograms (ERCs) were performed in 34 cases. The cholangiograms revealed various forms of filling defects in the dilated bile ducts. The most common cholangiographic features were amorphous filling defects in 15 cases, followed by tubular filling defects in 6 cases, and cast-like filling defects in 6 cases ( Fig. 1A-C ). There were 5 cases of CBD dilatation with no demonstrable filling defects and 2 cases of gallbladder filling defects without CBD involvement. Of tumor-related hemobilia, 6 of 10 patients with cholangiocarcinoma showed amorphous filling defects, and 11 of 14 patients with hepatocellular carcinoma showed tubular or cast-like filling defects. Of the 5 patients with CBD dilation with no demonstrable filling defects, 2 patients had underlying liver cirrhosis. The remaining 3 patients showed that large amounts of blood admixed with the bile was gushed out immediately after ERBD, representing massive hemobilia (Fig.   1D, E) . Two patients with gallbladder cancer showed amorphous filling defects within distended gallbladders (Fig. 1F) . (Table 3) . Those patients who were unfit for surgery were treated conservatively.
Management of hemobilia
There were 4 (10.5%) in-hospital mortalities related to hemobilia in the present study. Two patients died from sepsis due to the aggravation of suppurative cholangitis. One patient died from aggravating hepatic encephalopathy as a complication of liver cirrhosis. The remaining one patient died from hepatic failure, sepsis and multi-organ failure.
However, no mortalities were directly related to the bleeding.
DISCUSSION
Hemobilia, although uncommon, is challenging to recognize because the diagnosis and management is quite different from that of other causes of gastrointestinal bleeding.
Abdominal pain, melena or hematemesis, and obstructive jaundice are widely indicated as a typical triad of symptoms, presenting in 22-37.9% of hemobilia patients. 6, 7 Hemobilia usually involves minor bleeding and stops spontaneously in most cases. In the case of rapid bleeding, the blood flows rapidly into the duodenum, presenting as melena or hematemesis. In contrast, slow bleeding has the tendency to form clots and cause biliary obstruction because the blood does not mix with bile and forms separate layers due to the difference in gravity and surface tension. 8 The triad of symptoms occurred in only 13.5% of our cases. In the present study, abdominal pain and jaundice, indicating symptoms related to bile duct obstruction, were predominant symptoms; however, there were no cases presenting with hematemesis. The absence of hematemesis might be explained as follows: first, there was no massive bleeding in our cases; and second, the pyloric sphincter might prevent blood from the duodenum regurgitating into the stomach unless there was profuse bleeding.
In the past, the causes of hemobilia were accidental trauma in 38.6% of patients, followed by gallbladder stones in 14.9%, inflammation in 13%, vascular disorder in 10.7%, and tumors in 6.2% of the patients. 9 There has been a shift in the etiology of hemobilia over time. Currently, the main etiology of hemobilia is iatrogenic, of which needle biopsy or percutaneous intervention account for the main portion of cases of hemobilia due to increasing demand. [5] [6] [7] 10 Other causes such as cholecystitis, cholangitis, parasitic infestation, and hepatobiliary tumors were infrequently associated with hemobilia. Hepatobiliary malignancies, including hepatocellular carcinoma, were predominant causes of non-iatrogenic hemobilia in our study. Although we excluded hemobilia associated with percutaneous interventions of the bile duct or liver biopsy in this study, we experienced many cases of hemobilia occurring after PTC or liver biopsy in our hospital during the same study period. Most of hemobila caused by PTC were usually controlled spontaneously and significant bleeding necessitating embolization was very rare (data not shown).
Vessel injuries associated with liver biopsy or percutaneous intervention may have mostly been avoided with the help of ultrasonographic guidance.
Cholelithiasis is frequently associated with microscopic bleeding of the gallbladder and gallstone-related hemobilia accounts for 9% of reported cases of hemobilia. 7 Of the cases, 18.9% were related with cholangitis associated with CBD stones or cholecystitis in the present study. The stones in the gallbladder or CBD make direct mucosal damage and erode the vessel of the cystic artery, which usually leads to minor bleeding. 11 Moreover, acalculous cholecytitis may lead to hemobilia as well. It is postulated that the high pressure associated with acute cholecystits might cause erosion of gallbladder mucosa, subsequent ulceration of the vessel wall, and then bleeding into the bile duct. 12, 13 Neoplasm of the hepatobiliary tract is another important cause of hemobilia, with a reported incidence of 8.7%. 7 There have been increasing reports of malignancy-related hemobilia, including hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, gallbladder cancer, and hepatic metastasis. 14, 15 Hepatobiliary tumors, especially in the advanced stage, tend to cause hemobilia by direct invasion of surrounding vessels, not by the tumor itself. 16, 17 In our study, the incidence of tumor-related hemobilia was 75.6% of non-iatrogenic hemobilia, and 50% of the patients with the tumor-related hemobilia were associated with hepatocelluar carcinoma. The currently available diagnostic modalities include esophagogastroduodenoscopy, side-view endoscopy, abdominal CT, ultrasonography, and angiography. 18 Although CT angiography is very helpful to detect the bleeding point and mass lesions, it does not indicate the amount and rate of bleeding. An endoscopy has many advantages in that endoscopy can demonstrate fresh blood around the ampulla of Vater and exclude the other bleeding sites in the gastrointestinal tract. ERCP has played important roles in the diagnosis of hemobilia. 19 First, the color, rate, and amount of bleeding can be assessed by direct visualization. Second, cholangiogragm of the biliary tree could reveal the causes of hemobilia, type and site of filling defects, and degree of bile duct dilatation. With respect to the treatment of tumor-related hemobilia, other therapeutic modalities, including TAE, chemotherapy, or surgery, are options. In recent years, TAE is preferred to surgery, because TAE is less invasive and more effective, with a success rate of 80-100%. 6, 10, 27 Nevertheless, surgical treatment should be considered if embolization is unsuccessful or there are inflammatory diseases of the biliary system.
Cholecystectomy or CBD stone removal should be considered if hemobilia is associated with calculous cholecystitis or hemorrhagic cholecystitis. 25 The prognosis of hemobilia is largely dependent on the underlying causes. The prognosis of hemobilia associated with gallstones is good after cholecystectomy, however, that of hemobilia associated with malignancy is poor. 28 Recently, the mortality rate related to hemobilia has dropped from 12% to 5%. 6, 7 Although our in-hospital mortality rate was 10.5%, the causes of death were related to the aggravation of cholangitis or underlying diseases, but not to the severity of blood loss.
In conclusion, hemobilia, still an uncommon clinical manifestation, should be considered in the differential diagnosis of gastrointestinal bleeding and biliary obstruction. The most common non-iatrogenic causes of hemobilia were hepatobiliary malignancies and usually presented by biliary obstruction due to blood clots. This study suggests, whatever the cause, ERCP is a feasible and effective method in patients with hemobilia because ERCP cannot only confirm the hemobilia, but also manage the bleeding and bile duct obstruction. Therefore, endoscopic biliary drainage is recommended as the initial management of hemobilia to control biliary obstruction.
